Home Internet of Things Aerospace Apparel Energy Defense Health Care Logistics Manufacturing Retail

RFID News Roundup

GuardRFID unveils proximity tag exciter for room- or bed-level location ••• Bluewater Health selects Awarepoint RTLS ••• Texas A&M picks Apptricity RFID solution to manage Corps of Cadets uniforms ••• Norway Post expands implementation of Nedap's multi-access RFID solution ••• Thinfilm, Ypsomed partner on NFC-enabled injection systems for self-medication ••• Fujitsu outfits work van with RFID, GPS, sensors and more.
By Beth Bacheldor

Thinfilm, Ypsomed Partner on NFC-enabled Injection Systems for Self-Medication

Thin Film Electronics (Thinfilm), a Norwegian provider of printed electronics and smart systems, and the Ypsomed Group, a developer and manufacturer of injection systems for self-medication, have announced a partnership to incorporate Thinfilm's Near Field Communication (NFC) OpenSense technology in the YpsoMate autoinjector as a means of improving patient self-care compliance.

YpsoMate autoinjectors are disposable two-step injection systems that house prefilled glass or polymer syringes, Thinfilm reports, and are triggered by push-on-skin activation. Patients use autoinjectors to self-deliver periodic injections for the ongoing management of chronic conditions, such as rheumatoid arthritis or cardiovascular indications, making compliance a critical factor in their treatment plan.

The YpsoMate Smart autoinjector
Through the combination of the NFC OpenSense tags and a custom mobile app, Thinfilm explains, patients will be able to receive compliance assistance, such as adherence history, injection reminders, usage guidelines, refill instructions and authentication. In turn, the company notes, doctors will be able to track whether or not patients are adhering to daily self-medication requirements.

According to Thinfilm, NFC OpenSense tags are thin, flexible labels that can detect both the state before and after injection of an YpsoMate Smart autoinjector, as well as wirelessly deliver medication to patients through the simple tap of a smartphone, and record patients' interactions with the YpsoMate Smart device in the cloud. Each tag contains a unique identifier that makes it possible to track every YpsoMate Smart autoinjector to the individual item level. In addition, Thinfilm reports, the tag remains active even after the factory seal has been broken, enabling an extended dialogue between patients, doctors and brands.

Ypsomed will invest more than 50 million Swiss francs (approximately $50 million) during the coming years in the research and development of the new generation of injection and infusion systems. These systems support the administration of medications with intelligent electronic and software-based additional functions. Commercial availability of the systems has not yet been determined.

Login and post your comment!

Not a member?

Signup for an account now to access all of the features of RFIDJournal.com!

PREMIUM CONTENT
Case Studies Features Best Practices How-Tos
RFID JOURNAL EVENTS
Live Events Virtual Events Webinars
ASK THE EXPERTS
Simply enter a question for our experts.
TAKE THE POLL
JOIN THE CONVERSATION ON TWITTER
Loading
RFID Journal LIVE! RFID in Health Care LIVE! LatAm LIVE! Brasil LIVE! Europe RFID Connect Virtual Events RFID Journal Awards Webinars Presentations